Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Authors: Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park, Gaetano Maria De Ferrari, Zbigniew Gaciong, R Češka, Kálmán Tóth, Ioanna Gouni‐Berthold, José López‐Miranda, François Schiele, François Mach, Brian R. Ott, Estella Kanevsky, Armando Lira Pineda, Ransi Somaratne, Scott M. Wasserman, Anthony Keech, Peter S. Sever, Marc S. Sabatine - The Lancet 2017 cited by 677